<?xml version="1.0" encoding="UTF-8"?>
<p id="p0165">Chloroquine and hydroxychloroquine (HC) had received intense attention because of viral enzymes or processes inhibition especially in Iran, U.K, France. However, FDA revoked the emergency use authorization due to severe cardiac adverse events and other potential side effects. The potential benefits of chloroquine and HC no longer outweigh the potential risks for the authorized use [
 <xref rid="bb0235" ref-type="bibr">47</xref>]. HC is superior to chloroquine and reported positive results in some pre-clinical data in vitro and protocols. Both of these anti-malaria drugs might actually do more harm than good due to many side effects and should be prescribed not more than 7Â days. The main concerns in rare cases are cardiac arrest, retinal damage and ocular toxicity, particularly due to the fact that, people with heart conditions are at higher risk of severity [
 <xref rid="bb0240" ref-type="bibr">48</xref>].
</p>
